Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Invion ( (AU:IVX) ) has provided an announcement.
Invion Limited announced the results of its fully underwritten entitlement offer, raising approximately $1 million before costs through the issuance of new options. The offer was supported by eligible shareholders, with a 29% take-up rate, and the shortfall will be covered by underwriters, including the company’s Executive Chair and CEO. This financial maneuver is expected to bolster Invion’s operational capabilities and strengthen its market position in the life-science industry.
More about Invion
Invion is a life-science company focused on the research and development of Photosoft™ technology for treating various cancers, atherosclerosis, and infectious diseases. It holds exclusive license and distribution rights in multiple regions, including Australia, New Zealand, and parts of Asia Pacific. Invion is listed on the ASX and is developing Photosoft technology as a next-generation Photodynamic Therapy (PDT), which offers a less invasive treatment option with minimal side effects.
Average Trading Volume: 119,269
Technical Sentiment Signal: Sell
Current Market Cap: A$8.91M
See more data about IVX stock on TipRanks’ Stock Analysis page.